Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament for treating endoplasmic reticulum (ER) breast cancer

A breast cancer and drug technology, applied in drug combinations, diseases, anti-tumor drugs, etc., can solve the problems of negative breast cancer with high malignancy, easy recurrence and metastasis, and no effective treatment strategy

Inactive Publication Date: 2011-10-05
ZHENGZHOU UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among many breast cancer patients, about 30-40% are ER-negative breast cancer. Compared with ER-positive breast cancer, negative breast cancer has a higher degree of malignancy. Not only is it prone to recurrence and metastasis after surgery, but more importantly, it is ER-negative. Breast cancer patients are not sensitive to endocrine therapy drugs such as tamoxifen (TAM), and currently there is no effective treatment strategy except chemotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treating endoplasmic reticulum (ER) breast cancer
  • Medicament for treating endoplasmic reticulum (ER) breast cancer
  • Medicament for treating endoplasmic reticulum (ER) breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] A medicine (capsule) for treating ER-negative breast cancer, prepared in parts by weight from 5 parts of arsenic trioxide, 20 parts of tamoxifen, 10 parts of water-soluble collagen, and 165 parts of powdered sugar through the following method:

[0017] Dissolve water-soluble collagen in dilute citric acid with pH=3 to prepare a solution with a concentration of 0.5wt%, then take 1 part by weight of arsenic trioxide dissolved in water and mix with it; concentrate the mixed solution, dry it, pulverize it, and pass it through a 100-mesh sieve , to obtain arsenic trioxide collagen particles.

[0018] Mix the arsenic trioxide collagen granules, tamoxifen and powdered sugar evenly and put them into capsules, 200 mg per capsule.

[0019] Take 1 capsule per day for 14-28 consecutive days.

Embodiment 2

[0021] A medicine (tablet) for treating ER-negative breast cancer, prepared in parts by weight from 5 parts of arsenic trioxide, 5 parts of tamoxifen, 30 parts of water-soluble collagen, and 160 parts of microcrystalline cellulose through the following method:

[0022] Dissolving water-soluble collagen into dilute acetic acid with pH = 2 to prepare a solution with a concentration of 1 wt%, then dissolving 1 part by weight of arsenic trioxide in water and mixing it with it; concentrating, drying, and pulverizing the mixed solution and passing it through a 120-mesh sieve to obtain Arsenic trioxide collagen particles.

[0023] Mix arsenic trioxide collagen particles, tamoxifen and microcrystalline cellulose, and then directly compress into tablets, 200 mg per tablet.

[0024] One tablet per day for 14-28 consecutive days.

Embodiment 3

[0026] A medicine (granule) for treating ER-negative breast cancer, prepared in parts by weight from 5 parts of arsenic trioxide, 10 parts of tamoxifen, 50 parts of water-soluble collagen, and 135 parts of dextrin by the following method:

[0027] Dissolve water-soluble collagen in dilute acetic acid with pH=2 to prepare a solution with a concentration of 2wt%, then take 1 part by weight of arsenic trioxide dissolved in water and mix it with it; concentrate, dry and pulverize the mixed solution and pass it through an 80-mesh sieve, namely Obtain arsenic trioxide collagen particles.

[0028] The arsenic trioxide collagen particles, tamoxifen and dextrin are uniformly mixed, wetted with water mist, granulated, and passed through a 60-mesh sieve to obtain granules.

[0029] Take 200mg per day for 14-28 consecutive days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicament for treating endoplasmic reticulum (ER) breast cancer and belongs to the technical field of pharmacy. The active ingredients of the medicament are arsenic trioxide and tamoxifen. Experiments show that after being used together, the arsenic trioxide and the tamoxifen have obvious effect. To inoculated BALB / c-nu female nude mice, the tumor volume inhibition ratio of the composite medicament is up to 77.42 percent and the tumor weight inhibition ratio of the medicament is up to 76.28 percent. In addition, the formulation of the medicament is also improved, namely the arsenic trioxide is wrapped through collagen and then is mixed with the tamoxifen; and after a proper amount of diluent is added into the mixture, the mixture is prepared into oral formulations, such as powder, pills or capsules and the like. A normally used food component, namely water-soluble collagen, serves as a carrier and has high entrapment efficiency to the arsenic trioxide; the in-vivo retaining time of the arsenic trioxide can be prolonged while the side effect of the arsenic trioxide on gastrointestinal tract is reduced; long-time effective blood concentration is maintained; and while the effect of the medicament is maintained, great convenience is brought to patients and the injection pains of the patients are relieved.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a medicine for treating ER-negative breast cancer. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, and its incidence is increasing year by year. It has now become the first cause of death among women aged 40-55. Among many breast cancer patients, about 30-40% are ER-negative breast cancers. Compared with ER-positive breast cancers, negative breast cancers are more malignant. Not only are they prone to recurrence and metastasis after surgery, but more importantly, they are ER-negative. Breast cancer patients are not sensitive to endocrine therapy drugs such as tamoxifen (TAM), and currently there is no effective treatment strategy except chemotherapy. [0003] The change of DNA methylation status is considered to be the most common phenomenon in the process of tumor formation, and hypermethylation of gene promoter regi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/36A61K47/42A61P15/14A61P35/00A61K31/138
Inventor 王留兴陆士新樊青霞张伟杰王瑞林赵培荣
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com